This study is in progress, not accepting new patients
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Sandy Wong
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Sandy Wong
Assistant Professor, Medicine, School of Medicine. Authored (or co-authored) 98 research publications. Research interests: amyloidosis · plasma cell dyscrasias · multiple myeloma · MGUS · SMM
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Celgene
- Links
- BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting FDA Safety Alerts and Recalls
- ID
- NCT03486067
- Phase
- Phase 1 Multiple Myeloma Research Study
- Study Type
- Interventional
- Participants
- Expecting 220 study participants
- Last Updated